Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function

Delayed graft function (DGF) has long been identified as one of the main correlates of poor graft survival in cadaveric renal transplantation, but the factors that affect its onset and duration are not fully elucidated. The impact of two immunosuppressive protocols on the incidence and length of DGF among kidney transplant recipients of a suboptimal organ was evaluated. Patients were randomly treated with corticosteroids (CS); low-dose cyclosporine (CsA) and sirolimus (SRL; group 1; n 42); or CS, full dose CsA, and mycophenolate mofetil (group 2; n 48). All recipients received immunoprophylaxis with basiliximab. After 3 mo, group 1 discontinued CsA and continued with SRL, whereas group 2 continued the same treatment. The incidence of DGF was similar in the two groups (group 1 52.4%; group 2 58.3%), whereas its duration was significantly higher in the group 1 (19.0±6.0 versus 10.3±3.2 d; P 0.001). Both groups showed 100% actuarial graft and patient survival at 1-yr. Among DGF patients, serum creatinine (sCr) at discharge was significantly worse in group 1 (sCr, 3.0±1.0 versus 1.5±0.2 mg/dl; calculated creatinine clearance, 31.2±9.3 versus 61.1±10 ml/min; P 0.001). During the first year, the former group displayed a significant improvement of graft function, such that at 1-yr, no difference could be measured between groups (sCr, 1.8±0.5 versus 1.7±0.4 mg/dl; calculated creatinine clearance, 51.5±10.2 versus 53.3 ±9.4 ml/min). In conclusion, in de novo renal transplanted patients, the administration of SRL, in combination with low-dose CsA, is associated with a delayed recovery from DGF but does not worsen 1-yr graft function.